Double-stranded RNA to mimic viral infection for cancer immunotherapy

Jun 13, 2024 | Magazine: Clinical Cancer Research

Ana Martinez-Riaño 1 , Laura Mosteo 1 , Paula Molero-Glez 1 , Ivan Marquez-Rodas 2 , Ignacio Melero 1

Abstract

The presence of moieties denoting viral infection is crucial to mount powerful cytotoxic T-cell immune responses acting through innate receptors such as Toll-like receptor 3 (TLR3).

For cancer immunotherapy, several safe analogues of viral double-stranded RNA (dsRNA) are under clinical development following compelling evidence for efficacy in mouse models.

CITATION Clin Cancer Res. 2024 Jun 13. doi: 10.1158/1078-0432.CCR-24-0938

see publication in pubmed

Our authors

Imagen Dr. Ignacio Melero Bermejo, Inmunología

Dr. Ignacio Melero Bermejo Curriculum

Codirector Immunology and Immunotherapy Department

Navarre headquarters